About Pipeline Strategy Events Investors News Contact
 
  news  
 

Please see the links below for press releases and groundbreaking discoveries from Advanced Cancer Therapeutics

 

December 15, 2014 - ACT'S PFK-158 FEATURED IN CEO/CFO MAGAZINE; MD ANDERSON & UT HEALTH SCIENCE CENTER ADDED AS CLINICAL TRIAL SITES

November 24, 2014 - ACT'S PFKFB3 SELECTED AS ONE OF INFORMA AND KANTAR HEALTH 2014 TOP 10 MOST INTERESTING ONCOLOGY PROJECTS TO WATCH

June 4, 2014 - ACT ENTERS PHASE 1 HUMAN CLINICAL TRIALS WITH FIRST-IN-CLASS ANTI-CANCER DRUG CANDIDATE

February 11, 2014 - ACT was granted U.S. Patent 8,648,051 B2 “Antiproliferative Activity of G-Rich Oligonucleotides and Methods of the Using Same to Bind Nucleoin”

October 29, 2013 - ACT moved into The Nucleus facility located at 300 East Market Street, Louisville, KY 40202

October 15, 2013 - U.S. Patent 8,557,823 B2 'Family of PFKFB3 Inhibitors with Antineoplastic Properties' granted

April 12, 2013 - U.S. Granted Patent 8,410,070 B2 for PU27

December 22, 2012 - ACT awarded Federal and State SBIR awards totaling over $300,000

November 28, 2012 - ACT electronically submits IND Application for PFKFB3 to the FDA

October 11, 2012 - ACT AWARDED GRANT TO DEVELOP ANTI-CANCER DRUG FOR NOVEL CANCER METABOLISM TARGET

October 9, 2012 - U.S. Granted Patent 8,283,332 B2 for PFKFB3 to the FDA

April 3, 2012 - GRANTED US PATENT STRENGTHENS ACT ANTI-CANCER PRODUCT PORTFOLIO

February 14, 2012 - U.S. Granted Patent 8,114,850 B2 for GRO-777

January 30, 2012 - ACT CSO DR. GILLES TAPOLSKY TO PRESENT AT ANNUAL WORLD CANCER METABOLISM SUMMIT

October 19, 2011 - ACT CEO TO PRESENT AT MIDAMERICA HEALTHCARE VENTURE FORUM

May 3, 2011 - ADVANCED CANCER THERAPEUTICS TO ACQUIRE ANTISOMA DRUG

March 8, 2011 - ACT TO PRESENT PRECLINICAL DATA ON GLYCOLYSIS INHIBITORS AT AACR ANNUAL MEETING

August 10, 2010 - ACT COLLABORATES WITH BROWN CANCER CENTER RESEARCH SCIENTIST IN CANCER METABOLISM

July 1, 2010 - ACT RAISES $10 MILLION TO DEVELOP POTENTIALLY LIFESAVING CANCER TREATMENTS

February 23, 2010 - ACT RECEIVES FINAL $250,000 INVESTMENT FROM COMMONWEALTH SEED CAPITAL

February 3, 2010 - ACT FUNDS BROWN CANCER CENTER RESEARCH SCIENTIST TO ACCELERATE I.D. OF CLINICAL CANDIDATES

June 3, 2009 - ACT SECURES EXCLUSIVE LICENSE TO ANTI-CANCER THERAPEUTIC FROM U of L's BROWN CANCER CENTER

September 24, 2008 - JAMES R. RAMSEY, PH.D. JOINS ADVANCED CANCER THERAPEUTICS BOARD OF DIRECTORS

August 19, 2008 - ACT APPOINTS GILLES TAPOLSKY, PH.D. TO CHIEF SCIENTIFIC OFFICER

July 23, 2008 - ACT LICENSES TECHNOLOGY TO DEVELOP HUMAN PAPILLOMAVIRUS (HPV) VACCINE

June 25, 2008 - ACT BUSINESS MODEL AIMS FOR STEADY STREAM OF CANCER DRUGS

April 14, 2008 - EIGHT LOUISVILLE COMPANIES AWARDED FUNDING FROM KENTUCKY SCIENCE AND TECHNOLOGY CORP.

March 25, 2008 - ACT SECURES EXCLUSIVE LICENSE TO SECOND ANTI-CANCER THERAPEUTIC

March 4, 2008 - ACT OBTAINS EXCLUSIVE LICENSE TO DUAL MECHANISM ANTI-CANCER THERAPEUTIC

February 20, 2008 - ROBERT W. ROUNSAVALL, III JOINS ADVANCED CANCER THERAPEUTICS BOARD OF DIRECTORS

January 18, 2008 - STARTUP AIMS TO GET CANCER THERAPIES ON MARKET SOONER

January 18, 2008 - RANDALL B. RIGGS JOINS ADVANCED CANCER THERAPEUTICS AS PRESIDENT AND CEO

February 8, 2007 - U OF L SIGNS DEAL TO HELP SPEED CANCER THERAPIES TO MARKET